SCHEMBL25316356

SCHEMBL25316356

COC(=O)c1ccc(C2CC3(CCN2)CC(C)(F)C3)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HTT P42858 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 3/20 0.39
GAA P10253 3/20 0.39
HPGD P15428 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
ATM Q13315 2/20 0.39
GLA P06280 1/20 0.39
TSHR P16473 3/20 0.37
MAPT P10636 2/20 0.36
MAPK1 P28482 2/20 0.35
TP53 P04637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25318693 0.92 NPC1 (0.40) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL31140806 0.92 NPC1 (0.40) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL25901195 0.92 NPC1 (0.40) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL25318613 0.89 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL25619866 0.88 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL16400464 0.87 NPC1 (0.45) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL25316427 0.87 NPC1 (0.39) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL25318728 0.87 NPC1 (0.39) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL25316946 0.87 NPC1 (0.39) NPC1RAB9ASMN1; SMN2HTTMEN1
SCHEMBL25319179 0.87 NPC1 (0.39) NPC1RAB9ASMN1; SMN2HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115572-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS PHARMA AG (CH) 2025-04-10 US disclosed
CN-118696035-A Spiropiperidyl derivatives as complement factor B inhibitors and their use 诺华股份有限公司 2024-09-24 CN disclosed
WO-2023139534-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2023-07-27 WO disclosed
WO-2023139534-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115572-A1 SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF CFB, C1QBP, CFH NPC1 322/4885RAB9A 1785/4885SMN1; SMN2 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.